CAJ | 학술논문

淋巴细胞特异性蛋白酪氨酸激酶（Lymphocyte-specific protein tyrosine kinase,Lck or p56Lck）是一种在T细胞和自然杀伤细胞中表达的Src家族的细胞质酪氨酸激酶。在T细胞活化中,Lck的激活是一个必要步骤,故选择性抑制Lck可以产生免疫抑制作用。此外,Lck激酶在其他细胞中的异位表达可以诱发细胞发生癌变,因此抑制Lck还能起到抗癌作用。本文综述了Lck激酶作用机理及近年来的Lck激酶抑制剂的最新进展。
림파세포특이성단백락안산격매（Lymphocyte-specific protein tyrosine kinase,Lck or p56Lck）시일충재T세포화자연살상세포중표체적Src가족적세포질락안산격매。재T세포활화중,Lck적격활시일개필요보취,고선택성억제Lck가이산생면역억제작용。차외,Lck격매재기타세포중적이위표체가이유발세포발생암변,인차억제Lck환능기도항암작용。본문종술료Lck격매작용궤리급근년래적Lck격매억제제적최신진전。
The lymphocyte-specific kinase（Lck or p56Lck） was a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer cells.Activation of the Lck in T cell was a necessary step,and the selective inhibition of Lck can produce immunosuppression.In addition,ectopic expression of Lck in other cells can induce cells to become cancerous.Therefore,inhibition of expression of Lck can also prohibit cancer.Action mechanism of Lck and the latest progress of the Lck inhibitor in recent years were reviewed.